×
Molina Healthcare reported third-quarter 2026 adjusted earnings of $0.89 per share , topping the FactSet consensus estimate of $0.79 by $0.10. Total revenue came in at $11.08 billion , above the $10.86 billion consensus, though it declined 3.4% from $11.48 billion a year earlier.
Adjusted diluted earnings per share (EPS) came in at $6.99 , well above the roughly $4.70 consensus estimate. Operating revenue reached $50.4 billion , up 0.7% year over year and ahead of the approximately $49.3 billion analyst forecast.
UNH is the largest U.S. health insurer, while ELV is the second-largest and the leading Blue Cross Blue Shield licensee; both are considered managed-care bellwethers. UnitedHealth has raised its 2026 profit outlook three times this year on improving medical costs, while Elevance also lifted guidance and targets a return to at least 12% earnings-per-share growth in 2027.
UnitedHealth reported third quarter 2026 revenue of $112.7 billion and adjusted earnings per share (EPS) of $4.69 , beating the analyst consensus of roughly $4.14. The medical care ratio (MCR), the share of premium revenue paid out for medical claims, improved to 88.4% from 89.9% a year earlier and came in below expectations.
UnitedHealth reported third quarter 2026 revenue of $112.7 billion, slightly lower than a year ago but ahead of the $111.31 billion consensus estimate. Adjusted earnings per share (EPS) came in at $4.69, beating the roughly $4.14 Wall Street estimate and rising sharply from $2.92 a year earlier.
UnitedHealth Group (UNH) is scheduled to report third quarter 2026 results before the market opens on Tuesday, October 13, 2026. Analysts expect adjusted earnings of roughly $4.12 per share, up sharply from $2.92 in the prior-year quarter.
UnitedHealth Group (NYSE: UNH) reports its third quarter 2026 results on Tuesday, October 13, before the market opens. Wall Street consensus points to earnings of roughly $4.12 per share on revenue near $111.5 billion.
Humana reported that 95% of its Medicare Advantage members are now enrolled in plans rated at least four stars for 2027, a sharp rebound from roughly 20%–25% in recent years. The improved ratings restore Humana's eligibility for government quality bonus payments, a central pillar of the company's multi-year margin recovery plan.
Alignment Healthcare shares fell approximately 43% in the 30 days through October 9, 2026, sliding from a $13.03 close on September 9 to roughly $7.39. The decline was driven chiefly by a September 15 disclosure at Baird's Global Healthcare Conference and a subsequent CMS Medicare Advantage Star Ratings downgrade on the company's largest contract.
Two very different fertility plays: NIVF is an Asia-based fertility clinic operator pivoting into technology, while PGNY is a large U.S. fertility benefits administrator serving employers. Scale gap is extreme: Progyny generates well over $1 billion in annual revenue, while NewGenIvf is a micro-cap whose market value has shrunk into the single-digit millions.
Diverging catalysts: CLOV recently received a Medicare Advantage (MA) Star Rating upgrade to five stars, while ALHC suffered a downgrade on its largest California contract. Profitability inflection: Clover Health has turned GAAP (Generally Accepted Accounting Principles) profitable, whereas Alignment Healthcare's earnings path faces renewed cost and rating overhangs.
HUM is up +14.47% (+$56.02) to $443.14 versus the prior close of $387.12, with the surge ignited in premarket trading and extending into the regular session. The catalyst: CMS released 2027 Medicare Advantage Star Ratings, upgrading Humana's largest contract (H5216, ~2.4M members) from 3.5 to 4 stars, restoring 2028 quality bonus eligibility.
Alignment Healthcare shares fell roughly -28% to near $6.26, extending a slide that began in after-hours and premarket trading after CMS released 2027 Medicare Advantage Star Ratings. The catalyst: the company's largest California HMO contract (H3815), covering ~75% of membership, was cut to 3.5 stars from 4.0, falling below the 4-star threshold for federal bonus payments.
NIVF is a micro-cap fertility services operator in Asia with a highly volatile share price and repeated capital-raising activity, while PGNY is a scaled, profitable U.S. fertility benefits platform with a debt-free balance sheet. The two companies serve the same broad fertility theme but occupy very different ends of the market in terms of size, business model, and financial stability.
NIVF is a micro-cap, highly volatile restructuring story pivoting beyond its legacy fertility business, while PGNY is an established, profitable fertility-benefits platform with roughly $2 billion in market capitalization. Recent market activity has punished NIVF with steep percentage swings and ongoing dilution from capital raises, whereas PGNY has shown steadier, fundamentally supported trading.
ALHC is trading down -11.13% during regular market hours, sliding from a $12.94 prior close to roughly $11.50 intraday. The drop extends a selloff tied to a former executive's whistleblower lawsuit alleging operating costs were misclassified as capital expenditures to inflate adjusted EBITDA.
The selected price objective is $500 per share , roughly 28% above UNH's recent trading level near $389. The strongest bullish case rests on improving medical cost trends, an expected recovery in Optum margins, and a wave of recent analyst upgrades and price-target increases.
Selected price target: $40, roughly 22% above the most recent close and just above the highest published analyst target near $39. Strongest bullish factors: accelerating revenue growth, a major second-quarter earnings beat, raised full-year guidance, improving profitability, and a cash-rich balance sheet.
PGNY is down -9.67% in Friday's regular session, following a sharp after-hours selloff on Thursday after the company reported Q2 2026 results. The Q2 earnings beat analyst estimates (EPS of $0.55 vs. $0.34 consensus; revenue of $350.5M), but forward guidance disappointed investors.
Adjusted EPS (Earnings Per Share) of $2.58 crushed the Wall Street consensus estimate of roughly $1.83–$1.87, representing a beat of approximately 38–41%. Total revenue reached $106.1 billion, up 7.3% year-over-year and well above the analyst forecast of around $100 billion.